Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 2101-2107

  Yeh, Chia Ming ^a   Shay, Jacqueline ^a   Zeng, Ting Chuan ^a   Chou, Jian Liang ^a   Huang, Tim H M ^b   Lai, Hung Cheng ^c,d,e   Chan, Michael W Y ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^b University of Texas Health Science Center at San Antonio   (United States)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ARNTL; Circadian clock; Epigenetic modifications; Ovarian cancer; Tumor suppressor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; BISULFITE; CISPLATIN; DNA METHYLTRANSFERASE INHIBITOR; GSK 126; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ARNTL PROTEIN, HUMAN; HISTONE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CHEMOSENSITIVITY; CIRCADIAN RHYTHM; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HISTONE MODIFICATION; HUMAN; MICROARRAY ANALYSIS; ONCOGENE C MYC; OVARIAN CANCER CELL LINE; OVARY CANCER; PROMOTER REGION; RESTRICTION MAPPING; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; EPIGENETIC REPRESSION; GENE EXPRESSION REGULATION; GENETICS; OVARY TUMOR; PATHOLOGY;

ARNTL TRANSCRIPTION FACTORS; CIRCADIAN RHYTHM; CPG ISLANDS; DNA METHYLATION; EPIGENETIC REPRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 84907197942     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2627     Document Type: Article

References (42)

1. Sellix MT and Menaker M: Circadian clocks in the ovary. Trends Endocrinol Metab 21: 628-636, 2010.
2. Harrington ME: Exercise strengthens circadian clocks. J Physiol 590: 5929, 2012.
3. Green CB and Menaker M: Circadian rhythms. Clocks on the brain. Science 301: 319-320, 2003.
4. Falcon J: Cellular circadian clocks in the pineal. Prog Neurobiol 58: 121-162, 1999.
5. Stevens RG and Rea MS: Light in the built environment: Potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control 12: 279-287, 2001.
6. Hansen J: Risk of breast cancer after night-and shift work: Current evidence and ongoing studies in Denmark. Cancer Causes Control 17: 531-537, 2006.
7. Schernhammer ES, Laden F, Speizer FE, et al: Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 95: 825-828, 2003.
8. Canaple L, Kakizawa T and Laudet V: The days and nights of cancer cells. Cancer Res 63: 7545-7552, 2003.
9. Levin RD, Daehler MA, Grutsch JF, et al: Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer 93: 1202-1208, 2005.
10. Gery S and Koeffler HP: Circadian rhythms and cancer. Cell Cycle 9: 1097-1103, 2010.
11. Leonardi GC, Rapisarda V, Marconi A, et al: Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review). Oncol Rep 28: 418-428, 2012.
12. Yu EA and Weaver DR: Disrupting the circadian clock: Genespecific effects on aging, cancer, and other phenotypes. Aging (Albany, NY) 3: 479-493, 2011.
13. Rana S and Mahmood S: Circadian rhythm and its role in malignancy. J Circadian Rhythms 8: 3, 2010.
14. Paschos GK and FitzGerald GA: Circadian clocks and vascular function. Circ Res 106: 833-841, 2010.
15. Takahashi JS, Hong HK, Ko CH and McDearmon EL: The genetics of mammalian circadian order and disorder: Implications for physiology and disease. Nat Rev Genet 9: 764-775, 2008.
16. Hunt T and Sassone-Corsi P: Riding tandem: Circadian clocks and the cell cycle. Cell 129: 461-464, 2007.
17. Ripperger JA and Schibler U: Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. Nat Genet 38: 369-374, 2006.
18. Hsu CM, Lin SF, Lu CT, Lin PM and Yang MY: Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol 33: 149-155, 2012.
19. Tokunaga H, Takebayashi Y, Utsunomiya H, et al: Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand 87: 1060-1070, 2008.
20. Yang MY, Chang JG, Lin PM, et al: Downregulation of circadian clock genes in chronic myeloid leukemia: Alternative methylation pattern of hPER3. Cancer Sci 97: 1298-1307, 2006.
21. Baylin SB and Jones PA: A decade of exploring the cancer epigenome -biological and translational implications. Nat Rev Cancer 11: 726-734, 2011.
22. Seisenberger S, Peat JR and Reik W: Conceptual links between DNA methylation reprogramming in the early embryo and primordial germ cells. Curr Opin Cell Biol 25: 281-288, 2013.
23. Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT and Xu XX: Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 25: 5446-5461, 2006.
24. Yu Y, Fujii S, Yuan J, et al: Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann NY Acad Sci 983: 268-277, 2003.
25. Chan MW, Wei SH, Wen P, et al: Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 11: 7376-7383, 2005.
26. Chan MW, Huang YW, Hartman-Frey C, et al: Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 10: 908-919, 2008.
27. Chou JL, Su HY, Chen LY, et al: Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 90: 414-425, 2010.
28. Yeh KT, Chen TH, Yang HW, et al: Aberrant TGFbeta/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. Epigenetics 6: 727-739, 2011.
29. Su HY, Lai HC, Lin YW, Chou YC, Liu CY and Yu MH: An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124: 387-393, 2009.
30. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY and Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for aVβ3 and aVβ5 integrins and promotes cell motility. Cancer Res 62: 5358-5364, 2002.
31. McCabe MT, Ott HM, Ganji G, et al: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112, 2012.
32. Fu LN, Pelicano H, Liu JS, Huang P and Lee CC: The circadian gene period2 plays an important role in tumor suppression and DNA-damage response in vivo. Cell 111: 1055-1055, 2002.
33. Fu L and Lee CC: The circadian clock: Pacemaker and tumour suppressor. Nat Rev Cancer 3: 350-361, 2003.
34. Hoffman AE, Zheng T, Ba Y and Zhu Y: The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 6: 1461-1468, 2008.
35. Gery S, Komatsu N, Kawamata N, et al: Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res 13: 1399-1404, 2007.
36. Taniguchi H, Fernandez AF, Setien F, et al: Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res 69: 8447-8454, 2009.
37. Shih MC, Yeh KT, Tang KP, Chen JC and Chang JG: Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog 45: 732-740, 2006.
38. Mullenders J, Fabius AW, Madiredjo M, Bernards R and Beijersbergen RL: A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PloS one 4: E4798, 2009.
39. Jung CH, Kim EM, Park JK, et al: Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep 29: 2109-2113, 2013.
40. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
41. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003.
42. Vire E, Brenner C, Deplus R, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874, 2006.